Xu Dong Zhang Selected Research

Tunicamycin

1/2015	RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.
2/2014	Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress.
9/2009	Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
8/2008	Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.
2/2008	Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein.
10/2007	Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.
6/2007	Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xu Dong Zhang Research Topics

Disease

73	Melanoma (Melanoma, Malignant) 04/2022 - 05/2003
47	Neoplasms (Cancer) 04/2022 - 07/2003
5	Breast Neoplasms (Breast Cancer) 06/2022 - 05/2013
5	Neoplasm Metastasis (Metastasis) 04/2022 - 05/2013
5	Starvation 01/2022 - 02/2011
4	Colonic Neoplasms (Colon Cancer) 01/2018 - 06/2013
4	Necrosis 01/2018 - 12/2004
3	Nevus (Nevi) 04/2022 - 10/2006
3	Carcinogenesis 01/2021 - 09/2015
3	Stomach Neoplasms (Stomach Cancer) 01/2012 - 02/2008
2	Atherosclerosis 01/2022 - 11/2010
2	Genomic Instability 01/2020 - 01/2018
2	Hypoxia (Hypoxemia) 04/2018 - 01/2018
2	Neuroblastoma 01/2017 - 10/2014
2	Lung Neoplasms (Lung Cancer) 03/2016 - 02/2014
2	Sarcoma (Soft Tissue Sarcoma) 08/2015 - 01/2013
2	Disease Progression 07/2013 - 01/2010
2	AIDS-Related Complex (ARC) 08/2008 - 02/2008
1	Nevi and Melanomas 04/2022
1	Lymphatic Metastasis 04/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 06/2022 - 07/2003
15	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2019 - 05/2003
14	Small Interfering RNA (siRNA)IBA 09/2020 - 06/2007
10	Messenger RNA (mRNA)IBA 01/2021 - 03/2004
9	Long Noncoding RNAIBA 01/2022 - 01/2018
9	Phosphotransferases (Kinase)IBA 01/2022 - 02/2007
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 03/2004
8	Pharmaceutical PreparationsIBA 01/2021 - 02/2008
8	LigandsIBA 10/2012 - 03/2004
7	MicroRNAs (MicroRNA)IBA 10/2020 - 09/2011
7	ThapsigarginIBA 01/2015 - 10/2007
7	TunicamycinIBA 01/2015 - 06/2007
7	Death Domain ReceptorsIBA 10/2012 - 03/2004
7	Docetaxel (Taxotere)FDA Link 12/2010 - 02/2007
6	Cisplatin (Platino)FDA LinkGeneric 01/2013 - 02/2006
5	Biological ProductsIBA 01/2022 - 02/2006
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 04/2004
5	VemurafenibIBA 09/2017 - 01/2014
5	Mitogen-Activated Protein KinasesIBA 01/2016 - 02/2007
5	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2015 - 08/2007
5	DNA (Deoxyribonucleic Acid)IBA 04/2015 - 02/2006
5	Vincristine (Oncovin)FDA LinkGeneric 08/2014 - 02/2006
5	PLX 4720IBA 01/2014 - 02/2011
5	CaspasesIBA 02/2008 - 10/2003
4	TNF-Related Apoptosis-Inducing LigandIBA 12/2018 - 10/2003
4	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2013 - 05/2009
4	U 0126 (UO 126)IBA 08/2013 - 05/2003
4	Endoplasmic Reticulum Chaperone BiPIBA 10/2010 - 10/2007
4	Taxoids (Taxanes)IBA 12/2008 - 02/2007
4	Histone Deacetylase InhibitorsIBA 12/2006 - 10/2003
3	ParaffinIBA 06/2022 - 10/2006
3	sortilinIBA 04/2022 - 04/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2003
3	RNA (Ribonucleic Acid)IBA 10/2020 - 01/2013
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 06/2007
3	Protein Kinases (Protein Kinase)IBA 01/2018 - 03/2015
3	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 01/2018 - 03/2016
3	Inositol Polyphosphate 5-PhosphatasesIBA 03/2016 - 01/2013
3	dabrafenibIBA 01/2016 - 07/2013
3	ABT-737IBA 02/2013 - 02/2012
3	Protein Isoforms (Isoforms)IBA 03/2008 - 12/2004
3	suberic bishydroxamateIBA 02/2006 - 10/2003
2	AntibodiesIBA 06/2022 - 01/2018
2	Formaldehyde (Formol)FDA Link 06/2022 - 10/2006
2	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 04/2022 - 01/2018
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2022 - 01/2016
2	heparanaseIBA 10/2021 - 05/2013
2	Glutamine (L-Glutamine)FDA Link 01/2021 - 01/2021
2	Oxygen (Dioxygen)IBA 10/2020 - 01/2018
2	Oncogene Proteins (Oncogene Protein)IBA 10/2020 - 01/2018
2	Histones (Histone)IBA 01/2017 - 01/2013
2	Carrier Proteins (Binding Protein)IBA 04/2015 - 11/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2014 - 02/2009
2	obatoclaxIBA 01/2013 - 09/2009
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2010 - 11/2009
2	Apoptosis Regulatory ProteinsIBA 01/2010 - 10/2003
2	X-Box Binding Protein 1IBA 05/2009 - 02/2009
2	Glucose (Dextrose)FDA LinkGeneric 02/2009 - 10/2007
2	MitogensIBA 08/2008 - 08/2007
2	Caspase 8 (Caspase-8)IBA 02/2008 - 10/2003
2	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 10/2007 - 08/2007
2	Caspase 3 (Caspase-3)IBA 08/2007 - 10/2003
2	Bcl-2-Like Protein 11IBA 11/2006 - 10/2003
1	GAP-43 Protein (GAP 43 Protein)IBA 06/2022
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 06/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2022
1	Nerve Growth Factor (NGF)IBA 04/2022
1	Kynurenic Acid (Kynurenate)IBA 01/2022
1	Neuroprotective AgentsIBA 01/2022
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2022
1	Serine (L-Serine)FDA Link 01/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	RNA Precursors (Precursor, mRNA)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	GlutaminaseIBA 01/2021

Therapy/Procedure

13	Therapeutics 04/2022 - 01/2008
4	Drug Therapy (Chemotherapy) 01/2013 - 09/2003
2	Immunotherapy 01/2013 - 11/2009